Company: VERA
Filing Date: 2025-02-28
Form Type: S-8
Source: 0001193125-25-042606
Chunk: 0

Company: Vera Therapeutics, Inc.
Filing Date: 2025-02-28
Form: S-8
Chunk 0
---
As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter)

| Delaware                                 |     |         81-2744449 |
| (State or other jurisdiction of          
 incorporation or organization)           |     |   -I.R.S. Employer 
 Identification No. |
| 2000 Sierra Point Parkway, Suite 1200    
 Brisbane, California                     |     |              94005 |
| (Address of Principal Executive Offices) |     |          -Zip Code |

2021 Equity Incentive Plan 2021 Employee Stock Purchase Plan 2024 Inducement Plan (Full titles of the plans) Marshall Fordyce, M.D. President and Chief Executive Officer 2000 Sierra Point Parkway, Suite 1200 Brisbane, California 94005 (650) 770-0077 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Jodie Bourdet Julia Boesch Cooley LLP 3 Embarcadero Center, 20th Floor San Francisco, California 94111 (415) 693-2000 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2of the Exchange Act.

| Large accelerated filer |     | ☒ |     | Accelerated filer         |     | ☐ |
| Non-accelerated filer   |     | ☐ |     | Smaller reporting company |     | ☒ |
|                         |     |   |     | Emerging growth company   |     | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

Pursuant to General Instruction E of Form S-8, Vera Ther